Prime Medicine Inc

Prime Medicine, Inc. operates as a biotechnology company. It develops one-time curative genetic therapies, Prime Editors to address the wide spectrum of diseases by deploying its Prime Editing technology. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Wilson Disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson Disease pipeline landscape is provided which includes the disease overview and Wilson Disease treatment guidelines. The assessment part of the report embraces, in depth Wilson Disease commercial assessment and clinical assessment of the pipeline products under development.

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:

Prime Medicine to Participate in Upcoming Investor Conferences

Archer Aviation

Applied Blockchain Inc

CRISPR Therapeutics

Joby Aviation

Intuitive Machines Inc

Intellia Therapeutics

Navitas Semiconductor Corp

Rocket Lab USA

Serve Robotics Inc

SoundHound AI Inc

Virgin Galactic

These 12 innovative companies could deliver exponential returns over the next quarter century.

12 High-Growth Stocks That Could Deliver Parabolic Returns

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Aspen Aerogels

General Electric

Howmet Aerospace

Kratos Defense & Security Solutions

NVIDIA

Palantir Technologies

Taiwan Semiconductor Manufacturing

This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.

Why I Keep Buying These 14 Incredible Growth Stocks

-- On-track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, being held October 22-25, 2024 in Rome, and the American Association for the Study of Liver Diseases (AASLD), being held November 15-19, 2024 in San Diego.

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

RLX Technology

You've likely heard that penny stocks are high-risk investments, and if so, you've heard right.

Got $100? Consider Buying These 2 Penny Stocks in October

Changes are afoot at the company, and investors welcomed them.

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday.

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Bristol-Myers

On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of  ex vivo T-cell therapies.

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson's Disease Program Toward Expected IND Application and/or CTA in 1H 2026 --

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine is pioneering prime-editing technology for genetic disorders, with the potential for long-term growth despite its early-stage status. Rocket Lab USA is capturing market share in the expanding commercial space industry with its small satellite launch services and vertical-integration strategy.

2 Growth Stocks That Could Make You Richer

While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Arcutis Biotherapeutics

Bicycle Therapeutics Plc - ADR

Castle Biosciences Inc

Lexicon Pharmaceuticals

We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade

Moderna

Viking Therapeutics

Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero.

If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names

GitLab

Alphabet manages more than $7 billion in equity investments, including a publicly traded portfolio. Its biggest holding competes with Microsoft's Github.

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

Exact Sciences

Verve Therapeutics

The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.

Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024

Altimmune

Atossa Genetics

With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example.

Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024

The consensus price target hints at a 133.6% upside potential for Prime Medicine, Inc. (PRME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY.

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet

YouTube and Google parent Alphabet bought more GitLab and Prime Medicine stock in the first quarter.

Alphabet Bought Up Two Slumping Stocks

-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 --

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

News for Prime Medicine Inc Stock (PRME)